Search
Displaying results 81 - 90 of 108 in total
Metastatic Triple Negative Breast Cancers
go.drugbank.com/conditions/DBCOND0142223Platinum-resistant Fallopian Tube Cancer
go.drugbank.com/conditions/DBCOND0153829Locally advanced Urothelial Carcinoma
go.drugbank.com/conditions/DBCOND0089492Enristomig
go.drugbank.com/drugs/DB29060InvestigationalINBRX-105 is under investigation in clinical trial NCT03809624 (Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer).
Retifanlimab
go.drugbank.com/drugs/DB15766ApprovedInvestigational[L45603] Other monoclonal antibodies that block PD-1 include [pembrolizumab], [nivolumab] and [cemiplimab].
Adenocarcinoma, Renal
go.drugbank.com/conditions/DBCOND0126095Recurrent Cervical Cancer
go.drugbank.com/conditions/DBCOND0028795Muscle-invasive Bladder Cancer
go.drugbank.com/conditions/DBCOND0042339Platinum-resistant Epithelial Ovarian Cancer
go.drugbank.com/conditions/DBCOND0087629VIR-5818
go.drugbank.com/drugs/DB28582InvestigationalVIR-5818 is under investigation in clinical trial NCT05356741 (To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants